Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Introduces New PrimePCR™ Assays and Panels

Published: Tuesday, August 28, 2012
Last Updated: Tuesday, August 28, 2012
Bookmark and Share
Bio-Rad Laboratories, Inc.’s new PrimePCR assays and panels provide researchers with the industry’s only real-time PCR primer content that has been tested in the lab to meet the minimum information for publication of quantitative real-time PCR experiments (MIQE) guidelines.

“PCR primer design and assay validation are two of the most important steps for ensuring accurate, reproducible, and consistent quantitative PCR results,” said Jo Vandesompele, an author of the MIQE research paper. “Unfortunately, not all qPCR users are aware that qPCR assays in the industry have not always been fully validated.”

PrimePCR-plates_and_assays.gif
Other companies offering “validated” primer assays simply validate their primer design algorithm and do not wet-lab test each assay to ensure that they all meet MIQE guidelines. While all commercial assay providers use computer-based algorithms to design primers for qPCR, this alone does not guarantee that the assay will actually work in the lab. Thus, to ensure MIQE compliance, researchers still have to wet-lab validate their assays, which can waste time and resources.

“If a vendor claims to have wet-tested its primers, ask two questions to ensure your real-time PCR experiment will succeed,” said Sam Ropp, Marketing Manager of Bio-Rad’s Gene Expression Division. “One, did they actually test your primer pair, and two, was it up to MIQE standards? Testing amplification efficiency without a serial dilution won’t cut it.”

Meeting the MIQE Guidelines through Full Wet-Lab Validation
Bio-Rad collaborated with Jo Vandesompele and Jan Hellemans of Biogazelle, a qPCR data analysis and services company, to design, optimize, and experimentally validate every primer pair for the protein coding genes that make up the human transcriptome. All assays were designed following strict guidelines on maximum transcript coverage, minimal overlap with known SNPs, and spanning large introns where possible.

In addition, Bio-Rad validated every assay in the lab. Bio-Rad provides full transparency on the performance of each of its PrimePCR assays in the form of a standardized assay validation report. In accordance with MIQE guidelines, assays were rigorously evaluated for:
Efficiency — calculated from the results of a tenfold dilution series of synthetic templates; only assays that displayed good linear performance and efficiency were judged to be of sufficient quality
Specificity — all PCR products from cDNA were validated by massively parallel sequencing, which overcomes the limitations of melt curve analysis and gel electrophoresis
Sensitivity — nonspecific amplification was minimized by redesigning assays with unacceptably high background signal (mainly primer dimers)

PrimePCR products are available as individual SYBR® Green assays, preplated pathway and disease-specific panels, or custom configured plates. The panels were designed from canonical pathway maps provided via the systems biology solutions from the Life Sciences team at Thomson Reuters. The pathway curation and ranking strategy employed by Thomson Reuters and Bio-Rad ensures that the gene assays present on each real-time PCR pathway and collection plate are the most relevant for gene expression profiling based on differential expression studies and the frequency with which gene targets appear in the peer-reviewed literature.

To further support qPCR researchers, PrimePCR assays and panels are fully integrated with Bio-Rad’s CFX real-time PCR systems and CFX Manager™ 3.0 data analysis software for streamlined data collection and analysis.

For validation reports and more information on assay design and validation, please visit www.bio-rad.com/PrimePCR.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Presentations at the AACR Annual Meeting to Highlight Advances in Cancer Research Made Possible by Bio-Rad’s Droplet Digital™ PCR Technology
Tailoring Treatments and Tracking Mutations with Liquid Biopsies possible with ddPCR™ technology
Wednesday, April 22, 2015
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad Receives Award for QX100 Droplet Digital PCR System
Company receives Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future market leader of digital PCR technology award.
Thursday, March 14, 2013
Bio-Rad Acquires QuantaLife and Digital PCR Technology
Bio-Rad purchases QuantaLife for $162 million in cash plus potential future milestone payments.
Friday, October 07, 2011
Bio-Rad to Report Fourth-Quarter and Full-Year 2010 Financial Results Thursday, February 24, 2011
Company will discuss the results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Monday, March 14, 2011
Bio-Rad Reports Record Fourth-Quarter and Full-Year 2010 Financial Results
Fourth-quarter reported revenues were $533.7 million, up 7.8% compared to $495.1 million reported for the fourth quarter of 2009.
Monday, February 28, 2011
Bio-Rad Announces Public Offering of $425 Million Senior Notes
The interest rate and other terms of the Senior Notes are to be determined by negotiations between the Company and the underwriters of the Senior Notes.
Tuesday, December 07, 2010
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!